The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | The impact of allosteric HSP70 inhibitors on proteasome inhibitor resistance in multiple myeloma
Arun Wiita, MD, PhD, University of California, San Francisco, CA, discusses the potential use of allosteric HSP70 inhibitors to overcome proteasome inhibitor resistance in multiple myeloma. Pre-clinical experiments have shown that allosteric HSP70 inhibitors cause degradation of mitochondrial ribosome subunits, which could be used as a therapeutic strategy in patients refractory to first-line therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
